TENAX THERAPEUTICS INC (TENX)
Health Care · Clinical-stage cardiopulmonary therapeutics · NASDAQ
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib for pulmonary arterial hypertension.
What TENAX THERAPEUTICS INC does
Tenax Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. The company is advancing levosimendan for pulmonary hypertension and exploring imatinib for pulmonary arterial hypertension (PAH). Tenax finances operations through equity and debt securities to fund research and development of its therapeutic candidates. The company is incorporated in Delaware and headquartered in Chapel Hill, North Carolina.
Themes: ["cardiopulmonary therapies","pulmonary hypertension","PAH (pulmonary arterial hypertension)","clinical-stage development"]
Fundamentals
- Price$18.32 as of 2026-07-09 close
- Market cap$494M as of 2026-07-10
- 1-year return+216.8% as of 2026-07-09 close
- Net margin-10115.8% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE-56.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-82.9% as of 2026-07-10
- Beta0.95 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: levosimendag is in Phase 3 trials with no guarantee of regulatory approval or commercial success","Liquidity risk: the company has accumulated deficit of $383.2 million and significant ongoing operating losses requiring continued equity financing","Commercial execution risk: requires establishment of effective sales and marketing infrastructure and manufacturing partnerships to bring products to market"]
Competitors & peers
- Actelion (Janssen subsidiary)
- Gilead Sciences (PAH therapies)
- United Therapeutics
- Bayer
- Abbott
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.